APELLIS PHARMACEUTICALS INC - NOTE 3.500% 9/1

Historical Portfolio Holders from Q3 2020 to Q2 2024

All holders as of June 30, 2024
Q2 2024
Type / Class
Debt / NOTE 3.500% 9/1
Principal, excl. options Q2 2024
106M
Holdings value Q2 2024
$135M
Value change Q2 2024
+$14.5M
Grand Portfolio weight change Q2 2024
+0%
Number of holders
9
Number of buys Q2 2024
4
Number of sells Q2 2024
-5
Average buys Q2 2024 %
+0%
Average sells Q2 2024 %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Period Principal Value Change Price Investors
2024 Q2 $106M $135M +$14.5M $1.28 9
2024 Q1 $92.4M $151M -$2.23M $1.63 13
2023 Q4 $93.8M $153M +$9.62M $1.63 11
2023 Q3 $87.8M $111M -$27.6M $1.26 11
2023 Q2 $86.9M $208M +$10.5M $2.40 14
2023 Q1 $94.2M $175M +$774K $1.86 9
2022 Q4 $93.8M $144M -$5.52M $1.54 11
2022 Q3 $93.8M $181M -$78.7M $1.95 11
2022 Q2 $139M $206M -$92.9M $1.49 12
2022 Q1 $200M $315M +$5.61M $1.58 16
2021 Q4 $198M $299M +$5.56M $1.51 22
2021 Q3 $197M $242M -$366M $1.23 22
2021 Q2 $401M $746M +$577M $1.86 37
2021 Q1 $96.6M $136M -$192M $1.40 20
2020 Q4 $211M $357M +$38.1M $1.68 28
2020 Q3 $215M $232M +$232M $1.07 26